PROs in PAPILLON trial: amivantamab + chemo for EGFR Exon 20 NSCLC

PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLCПодробнее

PAPILLON: amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertionsПодробнее

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20Подробнее

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLCПодробнее

Amivantamab in patients with EGFR Ex20ins-mutated NSCLCПодробнее

MARIPOSA - Combination of Amivantamab & Lazertinib for Common EGFR Mutations in NSCLCПодробнее

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLCПодробнее

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLCПодробнее

Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 InsertionПодробнее

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLCПодробнее

A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLCПодробнее

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLCПодробнее

Post-progression analysis of MARIPOSA-2: amivantamab + chemo in EGFR+ NSCLCПодробнее

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLCПодробнее

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLCПодробнее

WCLC 2023 highlights: FLAURA2 and EGFR exon20-targeting TKIsПодробнее

MARIPOSA-2: second interim OS of amivantamab and chemotherapy in EGFR-m NSCLCПодробнее

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2Подробнее

The clinical impact of amivantamab and chemotherapy in EGFRm NSCLCПодробнее